Drug reference
Tegafur is a prodrug of fluorouracil. Gimeracil inhibits the degradation of fluorouracil and oteracil decreases the activity of fluorouracil in normal gastrointestinal mucosa. Immune system and malignant disease
PDF page 990
Treatment of advanced gastric cancer when used in combination with cisplatin ▶BY MOUTH ▶Adult: (consult local protocol)
PDF page 990
Dihydropyrimidine dehydrogenase deficiency
PDF page 990
Scottish Medicines Consortium (SMC) decisions SMC No. 802/12 The Scottish Medicines Consortium has advised (September 2012) that tegafur with gimeracil and oteracil (Teysuno ®) is accepted for restricted use within NHS Scotland for the treatment of advanced gastric cancer, when given in combination with cisplatin, in patients who are unsuitable for an anthracycline, fluorouracil, and platinum triplet first-line regimen.
PDF page 990
RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.
PDF page 990
→Appendix 1: tegafur
PDF page 990
▶Common or very common Anaemia. appetite abnormal. asthenia. constipation. cough. decreased leucocytes. dehydration. diarrhoea. dizziness. dry mouth. dysphagia. dyspnoea. electrolyte imbalance. embolism and thrombosis. eye disorders. eye inflammation. gastrointestinal discomfort. gastrointestinal disorders. haemorrhage. headache. hearing impairment. hiccups. hyperbilirubinaemia. hypertension. hypoproteinaemia. hypotension. insomnia. nausea. nerve disorders. neutropenia. oral disorders. taste altered. thrombocytopenia. vision disorders. vomiting ▶Uncommon Aerophagia. allergic rhinitis. alopecia. angina pectoris. anxiety. aphasia. arrhythmias. ascites. breast abnormalities. burping. cerebrovascular insufficiency. chills. coagulation disorders. confusion. depression. drowsiness. dysphonia. ear discomfort. encephalopathy. eosinophilia. fever. gout. hallucination. heart failure. hemiparesis. hyperaemia. hyperglobulinaemia. hyperglycaemia. hyperlipidaemia. hypertrichosis. hypovolaemic shock. increased leucocytes. increased risk of infection. joint disorders. limb discomfort. loss of consciousness. memory loss. movement disorders. mucositis. muscle complaints. muscle weakness. myocardial infarction. nail disorders. nasal complaints. neoplasm complications. nephrotoxicity. oedema. oesophageal spasm. pain. palpitations. pancytopenia. pericardial effusion. personality disorder. renal impairment. seizure. sensation abnormal. sepsis. sexual dysfunction. skin reactions. smell altered. sweat changes. syncope. throat complaints. thrombocytosis. tremor. urinary frequency increased. vasodilation. vertigo. weight changes ▶Rare or very rare Acute hepatic failure. chest discomfort. feeling cold. interstitial lung disease. local swelling. malaise. multi organ failure. pancreatitis acute. photosensitivity reaction. rhabdomyolysis. severe cutaneous adverse reactions (SCARs)
PDF page 990
Manufacturer advises effective contraception during and for up to 6 months after treatment.
PDF page 990
Avoid. See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.
PDF page 990
Discontinue breast-feeding.
PDF page 990
Manufacturer advises avoid if creatinine clearance less than 30 mL/minute. Dose adjustments Reduce dose if creatinine clearance 30–50 mL/minute—consult product literature.
PDF page 990
There can be variation in the licensing of different medicines containing the same drug. Capsule CAUTIONARY AND ADVISORY LABELS 23 ▶Teysuno (Nordic Pharma Ltd) Gimeracil 4.35 mg, Oteracil (as Oteracil potassium) 11.8 mg, Tegafur 15 mg Teysuno 15mg/4.35mg/11.8mg capsules | 126 capsule P £279.72 Gimeracil 5.8 mg, Oteracil (as Oteracil potassium) 15.8 mg, Tegafur 20 mg Teysuno 20mg/5.8mg/15.8mg capsules | 84 capsule P £248.40
PDF page 990
(consult local protocol)
First-line fragment. Read the complete Indications and Dose section above.
PDF page 990
